Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A patent review of topoisomerase I inhibitors (2016–present)

21 Jan 2021

Abstract excerpt

INTRODUCTION: Topoisomerases are important targets for therapeutic improvement in the treatment of some diseases, including cancer. Inhibitors and poisons of topoisomerase I can limit the activity of this enzyme in its enzymatic cycle. This fact implies an anticancer effect of these drugs, since most cancer cells are characterized by both a higher activity of topoisomerase I and a higher replication rate compared...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Chemical Reactions and Isotopes
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33475439
DOI: 10.1080/13543776.2021.1879051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A patent review of topoisomerase I inhibitors (2016–present)PMID 33475439Read ↗

Recent developments in topoisomerase-targeted cancer chemotherapySemantic proximity Read ↗

Novel camptothecin derivatives as topoisomerase I inhibitorsSemantic proximity Read ↗

Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase InhibitorsSemantic proximity Read ↗

Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer TherapySemantic proximity Read ↗

Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitorsSemantic proximity Read ↗

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial DrugsSemantic proximity Read ↗

Type I DNA TopoisomerasesSemantic proximity Read ↗

Recent development of multi-targeted inhibitors of human topoisomerase II enzyme as potent cancer therapeuticsSemantic proximity Read ↗

Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

Cracking the Code: Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugsSemantic proximity Read ↗

Targeting Topoisomerase I in the Era of Precision MedicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.